Completed EARLY_PHASE1 INTERVENTIONAL 5-arm NCT03928847

Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

Sponsor: Hal Chapman

Conditions Idiopathic Pulmonary Fibrosis

Interventions Epigallocatechin-3-gallate (EGCG)

Updated 9 times since 2019 Last updated: Dec 8, 2022 Started: Dec 1, 2017 Primary completion: May 31, 2019 Completion: May 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03928847, this EARLY_PHASE1 trial focuses on Idiopathic Pulmonary Fibrosis and remains completed. Sponsored by Hal Chapman, it has been updated 9 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Apr 2022 — Jan 2023 [monthly]

Completed EARLY_PHASE1

Status: Recruiting → Completed
Jan 2022 — Apr 2022 [monthly]

Recruiting EARLY_PHASE1

▶ Show 4 earlier versions

Feb 2021 — Jan 2022 [monthly]

Recruiting EARLY_PHASE1
Jan 2021 — Feb 2021 [monthly]

Recruiting EARLY_PHASE1
Jun 2020 — Jan 2021 [monthly]

Recruiting EARLY_PHASE1

Phase: PHASE1_PHASE2 → EARLY_PHASE1
May 2019 — Jun 2020 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Dec 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hal Chapman
National Heart, Lung, and Blood Institute (NHLBI)

Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Francisco, United States